Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Sinovac Biotech Ltd.

Sinovac Biotech Ltd. (SVA) Stock Overview

Explore Sinovac Biotech Ltd.’s financial performance, market position, analyst ratings, and future outlook.

SVA●NASDAQ
HealthcareMedical - Pharmaceuticals
$6.47
$0.00(0.00%)
U.S. Market opens in 52h 38m

Sinovac Biotech Ltd. (SVA)

Meyka AI Score

Z

Key Financials

Market Cap464.9M
P/E Ratio-7.80
EPS (TTM)$-1.14
ROE-0.01%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$6.47

SVA Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Sinovac Biotech Ltd. (NASDAQ: SVA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Sinovac Biotech Ltd.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of SVA on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $6.47 for the NASDAQ listing.

Key metrics behind Sinovac Biotech Ltd.'s NASDAQ-traded stock include a P/E ratio of -7.80 and a market capitalization of 464.9M. Combined with our AI analysis, these give both institutional and retail investors a clear view of SVA on the NASDAQ.

Price Performance (NASDAQ: SVA)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
N/A
6-Month Change
N/A
Year-to-Date (YTD) Change
N/A
1-Year Change
N/A
3-Year Change
N/A
5-Year Change
N/A
All-Time (Max) Change
729.49%

Contact Information

http://www.sinovacbio.com
86 10 8289 0088
No.39, SHANGDI West Road, Beijing, NaN, NaN

Company Facts

19,590 Employees
IPO DateSep 26, 2003
CountryCN

Frequently Asked Questions